Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • NCD 2025
NET Nurse
Donate

Home » Advocacy » Lutate access in NSW

Lutate access in NSW

  • May 4, 2015
For the last 5 years, the Unicorn Foundation working with the NSW Agency for Clinical Innovation, has developed and promoted a clinical pathway for the provision of Lutate in NSW hospitals.

As of January 2015 the NSW Ministry of health is supporting an evaluation of Lutate therapy at two sites – St George and Royal North Shore Hospitals. NET patients in NSW, if they are to be considered as potential recipients by their treating doctor of this therapy, need to be referred to and assessed by the NET MDT at either one (St George or Royal North Shore Hospitals) of the two NSW Lutate Services .

 

When patients are referred to one of the two NSW Lutate Services, they will be added to a NETs MDT Register and depending on availability, access and capacity of each centre, may be treated at either institution, rather than the most geographically convenient. Patients will also need to meet nationally agreed patient selection criteria before Lutate treatment can be considered.

 

For more information go to http://www.aci.health.nsw.gov.au/networks/nuclear-medicine/resources or print the referral protocol from the Unicorn Foundation (download below). It is important for all NSW NET patients to inform their treating doctors of this service to ensure that they are receiving the best possible care and clinical outcomes for the management of their NET.

https://neuroendocrine.org.au/wp-content/uploads/2020/03/NM-Lutate-referral-and-protocol_2015_01_12.pdf

Share this post

Recent posts

Nuclear Medicine Round Table

November 27, 2025

Celebrated Chef and Slow Food Pioneer Skye Gyngell Passed Away from Neuroendocrine Cancer

November 27, 2025

Attribute Preferences for SSAs in NETs Among Patients, Clinicians and Nurses in Australia

November 26, 2025

NECA Christmas and New Year Closure Details

November 18, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousSenate Inquiry – Availability of new, innovative and specialist cancer drugs in Australia
NextNET Nurse Petition UpdateNext

Related Posts

Nuclear Medicine Round Table

On Monday 17 November NECA attended the National Roundtable – Sustainable Pathways: Shaping the Future of Nuclear Medicines in Australia at Parliament House. Nuclear Medicine

NECA attends ACNNP Governance Group Day

NeuroEndocrine Cancer Australia (NECA) was pleased to attend the 2025 ACNNP Governance Group Day, held on 11 November at the Adelaide Convention Centre. The event

Equitable Access to Cancer Care: Reflections from Parliament House

On 30 October, NeuroEndocrine Cancer Australia (NECA) hosted a powerful event at Parliament House, Canberra, bringing together parliamentarians, clinicians, patient advocates, and industry leaders to discuss progress

Patient and Consumer Roundtable on Comparator Selection in HTA

On Monday 27 October our CEO attended a face to face Patient and Consumer Roundtable in Canberra with 10 other not-for-profit organisation. The Roundtable was

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin